This study is designed as a cross sectional, exploratory pilot study to examine the onset and progression of cancer-related fatigue in prostate cancer patients. The goal of this project is to report the effect of fatigue on quality of life and pilot a novel salivary biomarker to measure fatigue. One hundred men,diagnosed with prostate cancer and 200 men without prostate cancer will be recruited to participate in this study. Detailed medical and medication history will be reviewed to determine if subjects are eligible to participate in this study.All eligible participants will be recruited to participate in this study. All activities will be done during the patients regularly schedule visit with their oncologist at the CTRC. Each subject will sign an informed consent form indicating their willingness to participate afterwhich they will complete a battery of survey instruments and provide a 4 mL saliva sample. Saliva will be used to assess concentrations of a fatigue biomarkers in this study and banked for future research studies. Total length of time for study participation for each subject should be less than 1 hour.
Darpan Patel, Ph.D.
1. To determine the safety and Dose-limiting toxicities (DLTs) of Reolysin and chemotherapy (gemcitabine or irinotecan or 5FU) in combination with pembrolizumab in patients with advanced pancreatic adenocarcinoma who have progressed after ( or did not tolerate) first line treatment.
2.To determine the overall response rate (ORR), and progression-free survival (PFS) by immune-related response criteria , as well as overall survival (OS).
3. To determine the effects of Reolysin and pembrolizumab when administered in combination as determined by analysis of pre- and post-treatment biopsies and blood-based immune markers.
The purpose of this project is to establish a high-quality repository of male and female genitourinary tissue specimens with an associated database of relevant clinical, follow-up and outcome data. Development and maintenance of a high-quality repository is essential to the conduct of translational research for genitourinary cancer. When possible, specimens will be accrued by freezing fresh excess tissue removed at surgery or biopsy. No extra tissue will be removed during surgery expressly for the repository. Specimens will also be obtained from archival paraffin-embedded tissue. Clinical data will be obtained from tumor registry files, from subjects, or review of medical records.
Primary objective: Determine if our novel ex-vivo diagnostic assays, Circulating Tumor Cells Reporter Vector (CTC-RV) is capable of detecting a reporter signal from the collected blood and urine samples of patients with kidney cancer.